General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Prescription drug user fee agreements and general education about FDA approval polices and NIH research activities.
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Education about policies to improve newborn screening programs.
Duration: December 1, 2014
to
December 31, 2018
General Issues: Health Issues , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Budget/Appropriations
Spending: about $570,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cheryl Jaeger Sr policy advisor to Republican Whip Rep E Cantor
Shared employee, Speaker & Ofc of VA 7
Sr Policy Advisor to Majority Whip Rep R Blunt
Prof Staff Member to House Committee on E&C
Senior LA to Rep Christopher Cox
Sr. Policy Advisor to Majority Leader Rep E Cantor
Shared employee, Ofc of the Speaker & Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr Policy Adv, Rep Whip, Rep Cantor; Sr Policy Adv, Majority Whip Rep. Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
Sr. Policy Advisor to Republic Whip Rep Cantor
Sr. Policy Advisor to Majority Whip Rep Blunt
Sr. Policy Advisor to Republican Whip Rep Cantor
Sr. Policy Adv to Majority Leader Rep E Cantor
Shared employ, Ofc of Speaker & Ofc VA 7
Sr. Policy Advisor, Majority Leader Rep Cantor
Sr. Policy Advisor, Republican Whip Rep Cantor
Sr. Policy Advisor, Majority Whip, Rep Blunt
Sr. LA to Rep Christopher Cox
Karina Lynch Senate Committees on Aging and Government Affairs, Counsel
Senate Committees on Aging & Gov. Affairs
Senate Cmttes on Aging & Government Affairs
Senate Cmtes on Aging & Government Affairs
Andrew Jones Legislative Counsel, Rep Hinojosa; Legislative Director and Counsel, Rep. Lujan
Legislative Counsel, Rep. Hinojosa; Legislative Director and Counsel, Rep. Lujan
Susan Hirschmann COS, Rep Van Hilleary and Majority Whip
Cheryl Jager Sr. Policy Advto Majority Leader Rep E Cantor
George Olsen n/a
Erin Book Mullen n/a
Erin Mullen n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
Williams and Jensen, PLLC terminated an engagement in which they represented Biogen Idec on Jan. 18, 2019.
Original Filing: 301008751.xml
3rd Quarter, 2018
In Q3, Williams and Jensen, PLLC did no lobbying for Biogen Idec . The report was filed on Oct. 18, 2018.
Original Filing: 300988527.xml
2nd Quarter, 2018
In Q2, Williams and Jensen, PLLC did no lobbying for Biogen Idec . The report was filed on July 19, 2018.
Original Filing: 300969357.xml
1st Quarter, 2018
In Q1, Williams and Jensen, PLLC did no lobbying for Biogen Idec . The report was filed on April 20, 2018.
Original Filing: 300958346.xml
4th Quarter, 2017
In Q4, Williams and Jensen, PLLC did no lobbying for Biogen Idec . The report was filed on Jan. 11, 2018.
Original Filing: 300922926.xml
3rd Quarter, 2017
In Q3, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904792.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval polices and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education about policies to improve newborn screening programs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 19, 2017.
Original Filing: 300888306.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval polices and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education about policies to improve newborn screening programs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 12, 2017.
Original Filing: 300864241.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval polices and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education about policies to improve newborn screening programs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847588.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; H.R. 34, 21st Century Cures Act, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine and improve clinical trial data. S. 1878, Advancing Hope Act of 2016.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 34, 21st Century Cures Act, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); and improve clinical trail data; medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMMI Medicare Part B demonstration; General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to newborn screening programs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828445.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 1878, Advancing Hope Act of 2016.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMMI Medicare Part B demonstration; General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to newborn screening programs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 13, 2016.
Original Filing: 300809175.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMMI Medicare Part B demonstration; General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to newborn screening programs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 18, 2016.
Original Filing: 300792693.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMMI Medicare Part B demonstration; General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 14, 2016.
Original Filing: 300771682.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine; H.R. 2029.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies; H.R. 2029.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 15, 2015.
Original Filing: 300753513.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 15, 2015.
Original Filing: 300734917.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Williams and Jensen, PLLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 13, 2015.
Original Filing: 300714571.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 340 B program; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee).
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); medical research at NIH.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement, including Medicare payment policies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Williams & Jensen, PLLC. lobbied for Biogen Idec , earning $20,000. The report was filed on Jan. 16, 2015.
Original Filing: 300698090.xml
Lobbying Issues
General education about federal policies impacting biopharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Developing policies for the Energy and Commerce 21st Century Cures legislative initiative. Supporting policies to strengthen the National Newborn Screening Program, H.R. 1281.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Lobbying Issues
General education about federal policies impacting biopharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Developing policies for the Energy and Commerce 21st Century Cures legislative initiative. Supporting policies to strengthen the National Newborn Screening Program, H.R. 1281.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
Williams & Jensen, PLLC filed a lobbying registration on Dec. 9, 2014 to represent Biogen Idec, effective Dec. 1, 2014.
Original Filing: 300691839.xml
Issue(s) they said they’d lobby about: General education about federal policies impacting biopharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Developing policies for the Energy and Commerce 21st Century Cures legislative initiative. Supporting policies to strengthen the National Newborn Screening Program, H.R. 1281. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...